Citigroup Inc Reata Pharmaceuticals Inc Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$79.22 - $105.37 $666,636 - $886,688	8,415 Added 105.1%	16,422 $1.67 Million
Q1 2023 May 11, 2023	BUY	$30.85 - $93.17 $38,840 - $117,301	1,259 Added 18.66%	8,007 $727,000
Q4 2022 Feb 09, 2023	SELL	$22.15 - $42.11 $81,445 - $154,838	-3,677 Reduced 35.27%	6,748 $256,000
Q3 2022 Nov 10, 2022	SELL	$19.41 - $36.49 $28,513 - $53,603	-1,469 Reduced 12.35%	10,425 $262,000
Q2 2022 Aug 10, 2022	BUY	$20.71 - $36.5 $71,076 - $125,268	3,432 Added 40.56%	11,894 $361,000
Q1 2022 May 12, 2022	SELL	$24.12 - $39.6 $76,581 - $125,730	-3,175 Reduced 27.28%	8,462 $278,000
Q4 2021 Feb 10, 2022	SELL	$25.61 - $110.96 $397,185 - $1.72 Million	-15,509 Reduced 57.13%	11,637 $307,000
Q3 2021 Nov 10, 2021	BUY	$100.0 - $143.02 $2.71 Million - $3.88 Million	27,146 New	27,146 $2.73 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.